PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23303282-6	2013	Our modular complementary DNA (cDNA) design insures that selected MTX-resistant T cells co-express functionally relevant levels of the CD19-specific CAR and EGFRt.	Methotrexate	66-69	CD19 molecule	Homo sapiens	135-139	
10353096-12	1999	The lowering in the CD29+ subset population associated with depletion of CD19 B-cells after methotrexate therapy may limit abnormal CD4+ cell activation and reduce the migration of lymphocytes into inflamed synovium.	Methotrexate	92-104	CD19 molecule	Homo sapiens	73-77	
33897713-0	2021	MicroRNA Expression Differences in Blood-Derived CD19+ B Cells of Methotrexate Treated Rheumatoid Arthritis Patients.	Methotrexate	66-78	CD19 molecule	Homo sapiens	49-53	
9312762-6	1997	However, in the MTX treated group the percentage of CD19+ (15.1% before treatment vs 10.2% after 12 months MTX treatment (p < 0.05) and CD5+CD19+ B-cells was decreased.	Methotrexate	16-19	CD19 molecule	Homo sapiens	52-56	
9312762-6	1997	However, in the MTX treated group the percentage of CD19+ (15.1% before treatment vs 10.2% after 12 months MTX treatment (p < 0.05) and CD5+CD19+ B-cells was decreased.	Methotrexate	16-19	CD19 molecule	Homo sapiens	143-147	
8023589-11	1994	The percentage of CD19 positive cells decreased significantly during 12 months of treatment with MTX and CTX.	Methotrexate	97-100	CD19 molecule	Homo sapiens	18-22	
33897713-12	2021	Our results suggest important regulatory functions of miRNAs in blood-derived CD19+ B cells of MTX treated RA patients and motivate for future studies investigating the interactive mechanisms between miRNA and gene targets, as well as the possible predictive power of miRNAs for RA treatment response.	Methotrexate	95-98	CD19 molecule	Homo sapiens	78-82	
32417912-0	2020	Circulating CD19+CD24hiCD38hi regulatory B cells as biomarkers of response to methotrexate in early rheumatoid arthritis.	Methotrexate	78-90	CD19 molecule	Homo sapiens	12-16	
33363071-12	2020	A significant alteration was also demonstrated between patients treated with MTX and MTX/ADA group concerning CD 19+ B-cells (p3 = 0.042).	Methotrexate	77-80	CD19 molecule	Homo sapiens	110-115	
33363071-12	2020	A significant alteration was also demonstrated between patients treated with MTX and MTX/ADA group concerning CD 19+ B-cells (p3 = 0.042).	Methotrexate	85-88	CD19 molecule	Homo sapiens	110-115